Medpace (NASDAQ:MEDP) CEO Sells $274,978.62 in Stock

Key Points

• CEO August Troendle sold 458 Medpace shares at an average price of $600.39, generating $274,978.62. The sale reduced his direct ownership by 0.08%, leaving him with 603,978 shares.
• Medpace’s stock fell 0.6% to $578.50, while the company reported quarterly EPS of $4.25 and revenue of $707.33 million, both exceeding analyst expectations. Revenue increased 17.2% year over year.
• Analysts maintain a consensus “Hold” rating with an average price target of $584.18, despite several firms raising their targets; institutional investors own approximately 77.98% of the stock.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 458 shares of the company's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total value of $274,978.62. Following the transaction, the chief executive officer directly owned 603,978 shares in the company, valued at $362,622,351.42. The trade was a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Medpace Trading Down 0.6%

NASDAQ MEDP traded down $3.45 during trading on Friday, reaching $578.50. 215,633 shares of the company's stock were exchanged, compared to its average volume of 352,984. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The company's fifty day simple moving average is $533.75 and its 200-day simple moving average is $491.74. The firm has a market capitalization of $16.15 billion, a PE ratio of 33.91, a P/E/G ratio of 2.66 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Trading of Medpace

Several large investors have recently added to or reduced their stakes in the business. BOKF NA raised its holdings in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company's stock valued at $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC increased its position in Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company's stock worth $249,000 after buying an additional 21 shares during the last quarter. UMB Bank n.a. increased its position in Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company's stock worth $253,000 after buying an additional 24 shares during the last quarter. Schulhoff & Co. Inc. raised its holdings in Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Balefire LLC lifted its position in shares of Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company's stock worth $217,000 after buying an additional 26 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

MEDP has been the subject of a number of research analyst reports. Mizuho increased their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, Wall Street Zen lowered Medpace from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source